Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
5 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study.
Dermatol Ther (Heidelb). 2023 Jul;13(7):1517-1534. doi: 10.1007/s13555-023-00942-y. Epub 2023 Jun 15.
Dermatol Ther (Heidelb). 2023.
PMID: 37318750
Free PMC article.
Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial.
Paller AS, Seyger MMB, Magariños GA, Pinter A, Cather JC, Rodriguez-Capriles C, Zhu D, Somani N, Garrelts A, Papp KA; IXORA-PEDS Investigators.
Paller AS, et al. Among authors: rodriguez capriles c.
JAMA Dermatol. 2022 May 1;158(5):533-541. doi: 10.1001/jamadermatol.2022.0655.
JAMA Dermatol. 2022.
PMID: 35416908
Free PMC article.
Clinical Trial.
Item in Clipboard
Higher rates of skin clearance and efficacy in challenging body areas are associated with better health-related quality of life following ixekizumab maintenance treatment in pediatric patients with plaque psoriasis.
Hebert AA, Bobonich MA, Rodriguez Capriles C, Gallo G, Li L, Somani N, Ridenour T, Wang Y, Edson-Heredia E, Becker EM.
Hebert AA, et al. Among authors: rodriguez capriles c.
Pediatr Dermatol. 2022 Jan;39(1):55-60. doi: 10.1111/pde.14892. Epub 2021 Dec 20.
Pediatr Dermatol. 2022.
PMID: 34931346
Free PMC article.
Item in Clipboard
Population pharmacokinetic and exposure-efficacy analysis of ixekizumab in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS).
Jackson K, Chua L, Velez de Mendizabal N, Pitou C, Rodriguez Capriles C, Paller AS, Lansang P, Seyger MMB, Papp K; IXORA-PEDS study group.
Jackson K, et al. Among authors: rodriguez capriles c.
Br J Clin Pharmacol. 2022 Mar;88(3):1074-1086. doi: 10.1111/bcp.15034. Epub 2021 Sep 2.
Br J Clin Pharmacol. 2022.
PMID: 34378230
Free PMC article.
Item in Clipboard
Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS).
Paller AS, Seyger MMB, Alejandro Magariños G, Bagel J, Pinter A, Cather J, Keller S, Rodriguez Capriles C, Gontijo Lima R, Gallo G, Little CA, Edson-Heredia E, Li L, Xu W, Papp K; IXORA-PEDS study group.
Paller AS, et al. Among authors: rodriguez capriles c.
Br J Dermatol. 2020 Aug;183(2):231-241. doi: 10.1111/bjd.19147. Epub 2020 Jun 15.
Br J Dermatol. 2020.
PMID: 32316070
Free PMC article.
Clinical Trial.
Item in Clipboard
Cite
Cite